Zyprexa

March 10, 2008

In Ontario, the Honourable Mr. Justice Cullity certified the action as a class proceeding on February 6, 2007. The Defendants have received leave to appeal certain issues with respect to the decision and that appeal was scheduled to be heard on February 22, 2008.

In Quebec, where the action was certified on July 10, 2006, a court date was scheduled for March 5, 2008 to determine a timetable for the next steps in the action.

In British Columbia, the action is ongoing. Poyner Baxter continue to work with the national class counsel team. The progress in the actions in Ontario and Quebec have an effect on the steps that will ultimately be taken in British Columbia.

January 15, 2007

Class action suits have been filed in British Columbia, Alberta, Ontario and Quebec.  Poyner Baxter LLP is working with the national class counsel team to ensure the most effective representation possible for the class.

In Quebec, the class action, which includes residents of the Province of Quebec, was certified on July 10, 2006.

In Ontario, the class action certification motion, which will include the residents of all provinces and territories excluding Quebec, B.C. and Alberta, was heard before The Honourable Mr. Justice Cullity on November 22 – 27, 2006. On November 27, 2006, Mr. Justice Cullity announced that he had reserved his decision. It may take several months before his decision is released.

The case management judge assigned to the class action in British Columbia is The Honourable Mr. Justice Kelleher.  There are no hearings scheduled in British Columbia at this time.  Further dates will be scheduled once Mr. Justice Cullity’s decision has been released.

June 14, 2005

Poyner Baxter have today issued a press release regarding the Zyprexa class action. To view the press release, click here.

January 28, 2005

If you wish to be entered into our database of Zyprexa users please click here.

January 26, 2005

Poyner Baxter has filed a class action lawsuit against Eli Lilly Canada Inc. and its U.S. affiliate Eli Lilly and Company. Eli Lilly researched, developed, manufactured, sold, distributed and/or marketed a drug called Zyprexa (also known as Olanzapine) in Canada.

Zyprexa is among a group of drugs called the “atypical antipsychotic drugs” prescribed for the treatment of certain disorders such as schizophrenia and bipolar disorder.

The lawsuit alleges that Zyprexa has been associated with an increased risk of developing diabetes, hyperglycemia, pancreatitis, ketoacidosis and other injuries and that Eli Lilly knew or ought to have known that there were significantly increased risks of serious adverse health complications caused by ingesting Zyprexa.

To view the press release regarding Zyprexa, click here.

To view the complete Statement of Claim, click here.

This Web site is offered for information only and is not legal advice. Use of the site and sending or receiving information through it does not establish an attorney-client relationship. No one should act, or refrain from acting, based solely upon this information without seeking appropriate legal or other professional advice. In particular, you should obtain advice about limitation periods as it may affect your right to bring a legal action on your own behalf. Links to and from from this Web site do not state or imply a relationship between Poyner Baxter LLP and the linked entity.

Back